AZD5462 + dapagliflozin

**AZD5462 + dapagliflozin** is a combination of two orally administered small molecule drugs under investigation for the treatment of heart failure with moderate renal impairment. **AZD5462** is a selective oral agonist of the relaxin/insulin-like family peptide receptor 1 (RXFP1), acting as a pharmacological mimetic of relaxin H2 signaling. **Dapagliflozin** is a sodium-glucose cotransporter-2 (SGLT2) inhibitor already approved for heart failure, diabetes, and chronic kidney disease. In clinical trials, AZD5462 is administered on top of dapagliflozin as standard of care to evaluate additional renal and hemodynamic benefits in heart failure patients with impaired renal function. The combination aims to provide additive or complementary effects targeting both cardiac and kidney outcomes through distinct mechanisms[1][2][3][7].